Confronto

Carbetocin vs. Lanreotid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

37025-55-1

108736-35-2

Peso molecolare

nessun dato

1096.34 g/mol

Emivita

0.67 h

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Carbetocin

Carbetocin is an oxytocin receptor agonist with prolonged duration. It triggers a sustained contraction of the uterus after birth, preventing atonic hemorrhage — unlike oxytocin, without a multi-hour infusion.

Lanreotid

Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Carbetocin	Lanreotid
Germania	Su prescrizione	Su prescrizione
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Carbetocin and Lanreotid?: Carbetocin is classified as "Ricerca (altro)", while Lanreotid is classified as "Ricerca (altro)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Carbetocin or Lanreotid?: The highest available evidence level is "RCT sull'uomo" for Carbetocin and "RCT sull'uomo" for Lanreotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Carbetocin and Lanreotid in Germany and the United States?: Germania: Carbetocin — Su prescrizione, Lanreotid — Su prescrizione. Stati Uniti: Carbetocin — Non approvato, Lanreotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Carbetocin

Lanreotid

Germania

Su prescrizione

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between Carbetocin and Lanreotid?

Carbetocin is classified as "Ricerca (altro)", while Lanreotid is classified as "Ricerca (altro)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Carbetocin or Lanreotid?

The highest available evidence level is "RCT sull'uomo" for Carbetocin and "RCT sull'uomo" for Lanreotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Carbetocin and Lanreotid in Germany and the United States?

Germania: Carbetocin — Su prescrizione, Lanreotid — Su prescrizione. Stati Uniti: Carbetocin — Non approvato, Lanreotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.